title: Cigarette smoking and prostate cancer in a prospective US cohort study.
abstract: Smoking is an important risk factor for many cancers, yet the relationship between smoking and prostate cancer remains uncertain. We investigated whether smoking affected the risk of prostate cancers within a large prospective cohort study of dietary and environmental cancer risk factors among men ages 50 to 71 upon enrollment in 1995-1996 (n = 283,312). Cox proportional hazards regression models with hazard ratios (HR) and 95% confidence intervals (95% CI) were adjusted for age, race, education, height, body mass index, physical activity, family history of prostate cancer, diabetes, self-reported health status, prostate-specific antigen testing, digital rectal exam, total energy, alpha-tocopherol, calcium, alpha-linolenic acid, selenium, red meat, fish, and tomato intake. There were 14,810 nonadvanced and 1,830 advanced incident prostate cancers identified through 2003, and 394 men died of their disease through 2005. Current smokers had a decreased risk of nonadvanced prostate cancer (HR, 0.82; 95% CI, 0.77-0.88), but an increased risk of fatal prostate cancer (HR, 1.69; 95% CI, 1.25-2.27). Former smoking was also associated with decreased risk of nonadvanced prostate cancers (HR, 0.89; 95% CI, 0.86-0.92), but not fatal prostate cancers (HR, 1.03; 95% CI, 0.83-1.27). There was no apparent association between smoking and advanced prostate cancer. A number of biologically plausible mechanisms could explain these results, including the direct effects of carcinogens in tobacco smoke and the resulting changes in sex hormone or growth factor profiles. These findings suggest that current and former smokers may be at decreased risk of being diagnosed with prostate cancer and current smokers are at an increased risk of dying from prostate cancer.
authors.affiliation: Nutritional Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Department of Health and Human Services, Bethesda, Maryland 20892, USA. wattersj@mail.nih.gov
authors.forename: Joanne L
authors.initials: JL
authors.lastname: Watters
authors.forename: Yikyung
authors.initials: Y
authors.lastname: Park
authors.forename: Albert
authors.initials: A
authors.lastname: Hollenbeck
authors.forename: Arthur
authors.initials: A
authors.lastname: Schatzkin
authors.forename: Demetrius
authors.initials: D
authors.lastname: Albanes
mesh_terms: D000368:Aged; D015331:Cohort Studies; D004777:Environment; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D016016:Proportional Hazards Models; D011446:Prospective Studies; D011471:Prostatic Neoplasms / Q000453:epidemiology* / Q000401:mortality; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects / Q000453:epidemiology*; D011795:Surveys and Questionnaires; D014481:United States / Q000453:epidemiology
references.citation: Am J Epidemiol. 2000 Aug 1;152(3):279-86
references.pmid: 10933275
references.citation: Br J Cancer. 2004 Oct 18;91(8):1525-31
references.pmid: 15354219
references.citation: Int J Cancer. 2007 Oct 1;121(7):1571-8
references.pmid: 17450530
references.citation: Am J Epidemiol. 1991 Mar 1;133(5):437-41
references.pmid: 2000853
references.citation: N Engl J Med. 1999 Aug 5;341(6):427-34
references.pmid: 10432328
references.citation: J Urol. 2004 Apr;171(4):1543-6
references.pmid: 15017216
references.citation: Lancet. 2004 Apr 24;363(9418):1346-53
references.pmid: 15110491
references.citation: Cancer. 2008 Oct 15;113(8):2053-7
references.pmid: 18780337
references.citation: Ann Intern Med. 2008 Oct 7;149(7):461-71, W83-8
references.pmid: 18838726
references.citation: J Urol. 2008 Aug;180(2):658-62; discussion 662
references.pmid: 18554651
references.citation: Am J Epidemiol. 1988 Oct;128(4):796-805
references.pmid: 3421245
references.citation: Am J Epidemiol. 1999 Jan 15;149(2):106-15
references.pmid: 9921955
references.citation: Urology. 2007 Apr;69(4):721-5
references.pmid: 17445658
references.citation: J Natl Cancer Inst. 1996 Aug 21;88(16):1118-26
references.pmid: 8757191
references.citation: Cancer Causes Control. 2008 Feb;19(1):25-31
references.pmid: 17906959
references.citation: Epidemiol Rev. 2001;23(1):115-25
references.pmid: 11588835
references.citation: Langenbecks Arch Surg. 2006 Nov;391(6):603-13
references.pmid: 17031696
references.citation: Cancer. 2006 Jan 15;106(2):320-8
references.pmid: 16342294
references.citation: Am J Epidemiol. 2001 Dec 15;154(12):1119-25
references.pmid: 11744517
references.citation: J Clin Epidemiol. 2001 Sep;54(9):935-44
references.pmid: 11520654
references.citation: Ann Oncol. 2008 May;19(5):996-1002
references.pmid: 18212091
references.citation: Cancer Epidemiol Biomarkers Prev. 1999 Apr;8(4 Pt 1):277-82
references.pmid: 10207628
references.citation: Ann Oncol. 2001 Jun;12(6):761-5
references.pmid: 11484949
references.citation: J Clin Endocrinol Metab. 1994 Nov;79(5):1310-6
references.pmid: 7962322
references.citation: Cancer. 2007 Feb 15;109(4):675-84
references.pmid: 17211863
references.citation: Cancer Causes Control. 2009 Aug;20(6):877-86
references.pmid: 19277882
references.citation: Epidemiol Rev. 2007;29:88-97
references.pmid: 17478439
references.citation: CA Cancer J Clin. 2008 Mar-Apr;58(2):71-96
references.pmid: 18287387
references.citation: J Urol. 1995 Jul;154(1):153-7
references.pmid: 7776411
references.citation: Am J Epidemiol. 1997 Mar 1;145(5):466-75
references.pmid: 9048521
references.citation: Cancer Epidemiol Biomarkers Prev. 2003 Jul;12(7):604-9
references.pmid: 12869398
references.citation: Lancet Oncol. 2008 Jul;9(7):649-56
references.pmid: 18556244
references.citation: Cancer. 2007 Oct 1;110(7):1593-601
references.pmid: 17724671
references.citation: J Natl Cancer Inst. 2008 Feb 6;100(3):170-83
references.pmid: 18230794